Hepatitis B immunoglobulin (HBIG) withdrawal from combination lamivudine (LAM)/HBIG prophylaxis in liver transplant recipients.
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Lamivudine (Primary) ; Adefovir dipivoxil; Hepatitis B immune globulin
- Indications Hepatitis B
- Focus Therapeutic Use
- 02 Oct 2011 Additional lead trial centre identified as reported by ISRCTN: Current Controlled Trials record.
- 02 Oct 2011 Status changed from active, no longer recruiting to completed ISRCTN: Current Controlled Trials record.
- 22 Jul 2005 New trial record.